Company profile
COLLEGIUM PHARMACEUTICAL, INC
NASDAQ:COLLBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| JORNAY PM | approved | $46.1MQ2 2026 | 6 | approved |
| XTAMPZA ER | approved | $45.0MQ2 2026 | 0 | — |
| NUCYNTA | approved | $19.5MQ2 2026 | 0 | — |
| NUCYNTA ER | approved | $18.5MQ2 2026 | 0 | — |
| AZSTARYS | approved | $12.9M*Q2 2026 | 2 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01685684 | phase3 | completed | 2012-08-01 | 2014-06-01 | Collegium Pharmaceutical, Inc. | Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP) |
FDA applications (6)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212994 | 2021-05-07 | NDA | COMMAVE SUB LLC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC | |||||
Loading… | ||||||||
| NDA 209311 | 2018-08-08 | NDA | IRONSHORE PHARMACEUTICALS INC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC | |||||
Loading… | ||||||||
| NDA 208090 | 2016-04-26 | NDA | COLLEGIUM PHARMACEUTICAL INC | |||||
Loading… | ||||||||
| NDA 203794 | 2012-10-15 | NDA | COLLEGIUM PHARMACEUTICAL INC | |||||
Loading… | ||||||||
| NDA 200533 | 2011-08-25 | NDA | COLLEGIUM PHARMACEUTICAL INC | |||||
Loading… | ||||||||